• 
    

    
    

      99热精品在线国产_美女午夜性视频免费_国产精品国产高清国产av_av欧美777_自拍偷自拍亚洲精品老妇_亚洲熟女精品中文字幕_www日本黄色视频网_国产精品野战在线观看 ?

      Donanemab in Early Alzheimer's Disease

      2021-01-07 23:49:09MarkMintun
      四川生理科學(xué)雜志 2021年2期

      Mark A Mintun

      Background: A hallmark of Alzheimer's disease is the accumulation of amyloid-β (Aβ) peptide. Donanemab, an antibody that targets a modified form of deposited Aβ, is being investigated for the treatment of early Alzheimer's disease.

      Methods: We conducted a phase 2 trial of donanemab in patients with early symptomatic Alzheimer's disease who had tau and amyloid deposition on positron-emission tomography (PET). Patients were randomly assigned in a 1:1 ratio to receive donanemab (700 mg for the first three doses and 1400 mg thereafter) or placebo intravenously every 4 weeks for up to 72 weeks.The primary outcome was the change from baseline in the score on the Integrated Alzheimer's Disease Rating Scale (iADRS;range, 0 to 144, with lower scores indicating greater cognitive and functional impairment) at 76 weeks. Secondary outcomes included the change in scores on the Clinical Dementia Rating Scale-Sum of Boxes (CDR-SB), the 13-item cognitive subscale of the Alzheimer's Disease Assessment Scale (ADAS-Cog13), the Alzheimer's Disease Cooperative Study-Instrumental Activities of Daily Living Inventory (ADCS-iADL), and the Mini-Mental State Examination (MMSE), as well as the change in the amyloid and tau burden on PET.

      Results: A total of 257 patients were enrolled; 131 were assigned to receive donanemab and 126 to receive placebo. The baseline iADRS score was 106 in both groups. The change from baseline in the iADRS score at 76 weeks was -6.86 with donanemab and -10.06 with placebo (difference, 3.20; 95% confidence interval, 0.12 to 6.27; P = 0.04). The results for most secondary outcomes showed no substantial difference. At 76 weeks, the reductions in the amyloid plaque level and the global tau load were 85.06 centiloids and 0.01 greater, respectively, with donanemab than with placebo. Amyloid-related cerebral edema or effusions (mostly asymptomatic) occurred with donanemab.

      Conclusions: In patients with early Alzheimer's disease, donanemab resulted in a better composite score for cognition and for the ability to perform activities of daily living than placebo at 76 weeks, although results for secondary outcomes were mixed.Longer and larger trials are necessary to study the efficacy and safety of donanemab in Alzheimer's disease. (Funded by Eli Lilly;TRAILBLAZER-ALZ ClinicalTrials.gov number, NCT03367403.).

      北票市| 龙州县| 吉林市| 永州市| 炎陵县| 平凉市| 璧山县| 湘潭市| 高密市| 北宁市| 虎林市| 西华县| 泸州市| 萨迦县| 凤山县| 台江县| 宾川县| 晴隆县| 凌云县| 武冈市| 福安市| 武川县| 武安市| 兰州市| 商水县| 富阳市| 尉氏县| 鄯善县| 长沙市| 清新县| 巴青县| 汾西县| 同江市| 江孜县| 仁布县| 井冈山市| 武清区| 德清县| 沐川县| 临武县| 崇仁县|